
    
      Phase IV, prospective, multicenter, randomized, double-blind, placebo-controlled,
      academically funded clinical trial, with 6 months follow-up. A total of 354 patients will be
      recruited. Inclusion criteria are: 1) successful surgical or percutaneous repair of a cardiac
      valve at least one year before screening and 2) persistent moderate or severe PH, and 3)
      absence of any residual significant valvular lesion. Patients will be randomized 1:1 to
      received sildenafil 40 mg t.i.d. or placebo. The primary endpoint is a clinical composite
      score combining: all-cause mortality, hospital admission for heart failure, World Health
      Organization (WHO) functional class, and the patient global assessment score. Additional
      clinical and mechanistic secondary end-points are defined.
    
  